Theriva Biologics, Inc.

Theriva Biologics, Inc. (TOVX) is a publicly traded US company. Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.

The company reports trailing twelve-month revenue of $300,000 and net loss of $18.35M.

Key metrics include a return on equity of -32.5%, a debt-to-equity ratio of 0.41.

Investors tracking TOVX can follow price movements, analyst estimates, and fundamental changes directly through FINOTAUR's research tools.